EUVIMEDEUVIMED entdecken
Crossref

Mesalazine Suppresses Colorectal Cancer Liver Metastasis via the HDAC3 /Wnt/ β ‐Catenin Axis Through Downregulating Bacteroides fragilis Abundance

Zhou Yu, Yiwen Li, Jianping Wang iD

APMIS · 2025

DOI: 10.1111/apm.70078 ↗

Kurz gefasst

Fachartikel in der Zeitschrift APMIS, 2025. Verfasst von Zhou Yu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Colorectal and Anorectal Surgery, Jinhua Hospital Affiliated to Zhejiang University School of Medicine, Jinhua, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Mesalamine, Bacteroides fragilis, Liver Neoplasms. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Public welfare Project of Jinhua Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is characterized by high recurrence and metastasis, resulting in low patient survival. Dysbiosis of intestinal flora increases CRC metastasis risk. Mesalazine, an anti‐inflammatory drug with proven antitumor activity, is commonly used to treat CRC in patients with inflammatory bowel disease, but whether it mediates CRC hepatic metastasis by affecting key flora is unknown. An animal model of CRC liver metastasis was established by injecting HCT116 cells into the spleens of mice and treated with mesalazine. Mouse feces were collected for 16S rRNA sequencing to analyze the abundance of intestinal flora. In vitro experiments demonstrated that mesalazine inhibited proliferation, migration, and invasion of CRC by modulating Bacteroides fragilis . Rescue experiments validated molecular mechanisms. Mesalazine inhibited CRC hepatic metastasis and reduced the abundance of Bacteroides fragilis in the feces of CRC hepatic metastatic mice by 16S rRNA sequencing analysis. In vitro experiments showed that mesalazine inhibited proliferation, migration, and invasion of CRC by affecting Bacteroides fragilis , mainly through the histone deacetylase 3 (HDAC3)/Wingless/Int/Beta‐catenin (Wnt/ β ‐catenin) axis. The study elucidated the mechanism by which mesalazine inhibited CRC liver metastasis through the HDAC3/Wnt/ β ‐catenin axis by affecting the abundance of Bacteroides fragilis , which provided a new idea for CRC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsMesalamineBacteroides fragilisLiver NeoplasmsHistone DeacetylasesWnt Signaling PathwayAnimalsHumansMiceHCT116 CellsCell ProliferationGastrointestinal MicrobiomeCell MovementMaleDown-RegulationFecesDisease Models, AnimalHistone Deacetylase 3

Stichwörter der Autor:innen

Bacteroides fragilisHDAC3Wnt/β‐catenincolorectal cancermesalazine

Substanzen

MesalamineHistone DeacetylasesHistone Deacetylase 3

Autor:innen und Institutionen

  • Colorectal and Anorectal Surgery, Jinhua Hospital Affiliated to Zhejiang University School of Medicine, Jinhua, China.

ORCID-Profile: Jianping Wang

Förderung

  • Public welfare Project of Jinhua Science and Technology Bureau

Zitieren

APA

Yu, Z., Li, Y., & Wang, J. (2025). Mesalazine Suppresses Colorectal Cancer Liver Metastasis via the HDAC3 /Wnt/ β ‐Catenin Axis Through Downregulating Bacteroides fragilis Abundance. APMIS. https://doi.org/10.1111/apm.70078

Vancouver

Yu Z, Li Y, Wang J. Mesalazine Suppresses Colorectal Cancer Liver Metastasis via the HDAC3 /Wnt/ β ‐Catenin Axis Through Downregulating Bacteroides fragilis Abundance. APMIS. 2025. doi:10.1111/apm.70078

BibTeX
@article{Yu2025,
  author = {Yu, Zhou and Li, Yiwen and Wang, Jianping},
  title = {Mesalazine Suppresses Colorectal Cancer Liver Metastasis via the HDAC3 /Wnt/ β ‐Catenin Axis Through Downregulating Bacteroides fragilis Abundance},
  journal = {APMIS},
  year = {2025},
  doi = {10.1111/apm.70078}
}
Kostenlos starten →